Integrated Diagnostics Holdings PLC Notice of Results (2617S)
12 November 2021 - 11:03PM
UK Regulatory
TIDMIDHC
RNS Number : 2617S
Integrated Diagnostics Holdings PLC
12 November 2021
Integrated Diagnostics Holdings Plc Notice of Results
12 November 2021
(London) Integrated Diagnostics Holdings ("IDH," "the Group," or
"the Company"), a leading consumer healthcare company with
operations in Egypt, Jordan, Sudan and Nigeria, will publish its r
esults for the nine-month period ended 30 September 2021 on
Tuesday, 16 November 2021 at 7am (UK).
An analyst and investor call will be hosted at 1pm (UK) | 3pm
(Egypt) on Thursday, 18 November 2021. You can access the call by
clicking on this link , and you may dial in using the conference
call details below:
-- Event number: 2374 489 7777
-- Event password: C5wWfFNBa46
For more information about the event, please contact:
halaa@EFG-HERMES.com
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 2,000 diagnostics tests. From its base of 495
branches as of 30 June 2021, IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern, African, and Asian markets where its model is well-suited
to capitalise on similar healthcare and consumer trends and capture
a significant share of fragmented markets. IDH has been a
Jersey-registered entity with a Standard Listing on the Main Market
of the London Stock Exchange (ticker: IDHC) since May 2015 with a
secondary listing on the EGX since May 2021 (ticker: IDHC.CA).
Learn more at idhcorp.com .
The person responsible for arranging the release of this
announcement is Nancy Fahmy, Investor Relations Director at
IDH.
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGZMMMZZFGMZM
(END) Dow Jones Newswires
November 12, 2021 07:03 ET (12:03 GMT)
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Apr 2023 to Apr 2024